EMT Targeting Vaccination, Concurrent with Chemoimmunotherapy, in Advanced NSCLC
Abstract
Immunotherapy is a significant treatment advance for non-small cell lung cancer (NSCLC) and the only therapy that can lead to long term survival, although this occurs in less than 20% of patients. Patients receiving chemoimmunotherapy vs chemotherapy alone demonstrated a significantly longer survival. Despite this improvement, the majority of patients die within 2 years of diagnosis. High levels of tumor infiltrating lymphocytes (TIL) predict response to immune checkpoint inhibitor (ICI) therapy in animal models and lung cancer patients. Unfortunately, high levels of TIL are found in less than 10% of patients and a quarter of NSCLC patients have no evidence of TIL. Presence of CD8+ TIL is an independent prognostic variable in NSCLC and is associated with improved clinical outcomes. Strategies, such as vaccines, to increase CD8+ TIL could synergize ICI and improve survival in all NSCLC patients with advanced disease. Vaccines are able to induce tumor specific immunity and increase CD8 TIL in animal models.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2022
- Accession Number
- AD1179179
Entities
People
- Laura Riolobos
Organizations
- University of Washington